Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol

Gregory, John W. ORCID:, Carter, Kymberley, Cheung, Wai Yee, Holland, Gail, Bowen-Morris, Jane, Luzio, Stephen, Dunseath, Gareth, Tree, Timothy, Yang, Jennie Hsiu Mien, Marwaha, Ashish, Alhadj Ali, Mohammad, Bashir, Nadim, Hutchings, Hayley Anne, Fegan, Greg W., Stenson, Rachel, Hiles, Stephen, Marques-Jones, Susie, Brown, Amy, Tatovic, Danijela ORCID: and Dayan, Colin ORCID: 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11 (10) , e049595. 10.1136/bmjopen-2021-049595

[thumbnail of e049595.full.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


Introduction Most individuals newly diagnosed with type 1 diabetes (T1D) have 10%–20% of beta-cell function remaining at the time of diagnosis. Preservation of residual beta-cell function at diagnosis may improve glycaemic control and reduce longer-term complications. Immunotherapy has the potential to preserve endogenous beta-cell function and thereby improve metabolic control even in poorly compliant individuals. We propose to test ustekinumab (STELARA), a targeted and well-tolerated therapy that may halt T-cell and cytokine-mediated destruction of beta-cells in the pancreas at the time of diagnosis. Methods and analysis This is a double-blind phase II study to assess the safety and efficacy of ustekinumab in 72 children and adolescents aged 12–18 with new-onset T1D. Participants should have evidence of residual functioning beta-cells (serum C-peptide level >0.2nmol/L in the mixed-meal tolerance test (MMTT) and be positive for at least one islet autoantibody (GAD, IA-2, ZnT8) to be eligible. Participants will be given ustekinumab/placebo subcutaneously at weeks 0, 4 and 12, 20, 28, 36 and 44 in a dose depending on the body weight and will be followed for 12 months after dose 1. MMTTs will be used to measure the efficacy of ustekinumab for preserving C-peptide area under the curve at week 52 compared with placebo. Secondary objectives include further investigations into the efficacy and safety of ustekinumab, patient and parent questionnaires, alternative methods for measuring insulin production and exploratory mechanistic work.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: Re-use permitted under CC BY.
Publisher: BMJ Publishing Group
ISSN: 2044-6055
Date of First Compliant Deposit: 17 February 2022
Date of Acceptance: 5 September 2021
Last Modified: 05 May 2023 09:14

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics